Featured Publications
Development of Syngeneic Murine Glioma Models with Somatic Mismatch Repair Deficiency to Study Therapeutic Responses to Alkylating Agents and Immunotherapy
Bhatt D, Sundaram R, López K, Lee T, Gueble S, Vasquez J. Development of Syngeneic Murine Glioma Models with Somatic Mismatch Repair Deficiency to Study Therapeutic Responses to Alkylating Agents and Immunotherapy. Current Protocols 2025, 5: e70097. PMID: 39995104, DOI: 10.1002/cpz1.70097.Peer-Reviewed Original ResearchConceptsImproved response to immune checkpoint blockadeGlioma modelResponse to immune checkpoint blockadeAlkylating agentsImmune checkpoint blockadeIncrease tumor immunogenicityMurine glioma modelMurine glioma cell lineResponse to alkylating agentsResistance to temozolomideDNA repair genotypesMMR deficiencyAntitumor immunityCheckpoint blockadeTumor immunogenicityMedian survivalImmunocompetent modelDismal prognosisMismatch repairMismatch repair deficiencyGlioma cell linesIntracranial tumorsAlkylating chemotherapySomatic lossSomatic acquisition
2022
Antigen-independent tumor targeting by CBX-12 (alphalex™–exatecan) induces long-term antitumor immunity
Gayle S, Paradis T, Jones K, Vasquez J, Paralkar V. Antigen-independent tumor targeting by CBX-12 (alphalex™–exatecan) induces long-term antitumor immunity. Immunotherapy 2022, 14: 1467-1480. PMID: 36597724, DOI: 10.2217/imt-2022-0121.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCamptothecinCell Line, TumorImmunityImmunotherapyNeoplasmsTumor MicroenvironmentConceptsLong-term antitumor immunityAntitumor immunityImmune recognition of tumor cellsInducer of immunogenic cell deathRecognition of tumor cellsAnti-PD-1Immunogenic cell deathDelayed tumor growthExpression of MHC-1Immunotherapy combinationsPH-sensitive peptidesComplete responseCT26 modelPD-L1Tumor cellsTumor targetingTumor growthCured animalsClinical trialsELISA assayImmunotherapyMHC-1Cell deathFunctional assaysImmunity
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply